Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Interest & Investment Income (2021 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Interest & Investment Income for 5 consecutive years, with $472000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Interest & Investment Income fell 25.2% year-over-year to $472000.0, compared with a TTM value of $2.2 million through Sep 2025, down 16.23%, and an annual FY2024 reading of $2.7 million, down 6.92% over the prior year.
  • Interest & Investment Income was $472000.0 for Q3 2025 at Barinthus Biotherapeutics, down from $523000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $1.6 million in Q1 2023 and bottomed at $2000.0 in Q1 2021.
  • Average Interest & Investment Income over 5 years is $638187.5, with a median of $601000.0 recorded in 2023.
  • The sharpest move saw Interest & Investment Income skyrocketed 4050.0% in 2022, then plummeted 80.86% in 2023.
  • Year by year, Interest & Investment Income stood at $2000.0 in 2021, then surged by 66250.0% to $1.3 million in 2022, then tumbled by 56.97% to $571000.0 in 2023, then grew by 11.56% to $637000.0 in 2024, then decreased by 25.9% to $472000.0 in 2025.
  • Business Quant data shows Interest & Investment Income for BRNS at $472000.0 in Q3 2025, $523000.0 in Q2 2025, and $556000.0 in Q1 2025.